Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00138840 · ClinicalTrials.gov registry record · Phase 2
Study of STA-5326 Mesylate in Patients With Moderate to Severe Crohn's Disease
A Phase 2 study, sponsored by Synta Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 282
- Enrollment target
NCT00138840: Completed Phase 2 study, sponsored by Synta Pharmaceuticals.
NCT00138840 is a Phase 2 study that has completed, run by Synta Pharmaceuticals. The registered enrollment target is 282 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00138840, a Phase 2 study, has completed, sponsored by Synta Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 282 participants
- Enrollment target
Study Summary
STA-5326 is an experimental drug that has been shown to block the release of interleukin-12 from peripheral blood mononuclear cells. Given this activity on the immune system, STA-5326 mesylate is a potential treatment for various autoimmune diseases, such as Crohn's disease, that are mediated by the inappropriate expression of Th1 cytokines. This study is evaluating the use of STA-5326 mesylate in patients with moderate to severe, active Crohn's disease. Study visits include a screening visit, 9 treatment period visits over 6 months and a follow-up visit that will occur 30 days following the end of treatment. Study drug treatment will continue for up to 6 months.
Interventions
- DRUG STA-5326 mesylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 282 participants |
| Start Date | 2005-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00138840
The ClinicalTrials.gov registry entry for NCT00138840 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 282 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Synta Pharmaceuticals, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which STA-5326 mesylate is the first listed.
NCT00138840 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00138840 about?
NCT00138840 is a clinical study titled "Study of STA-5326 Mesylate in Patients With Moderate to Severe Crohn's Disease". STA-5326 is an experimental drug that has been shown to block the release of interleukin-12 from peripheral blood mononuclear cells. Given this activity on the immune system, STA-5326 mesylate is a potential treatment for various autoimmune diseases, such as Crohn's disease, that are mediated by the...
What is the current status of trial NCT00138840?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 282 participants. The study started on 2005-08.
What interventions are being tested in trial NCT00138840?
The interventions under investigation include: STA-5326 mesylate (DRUG).
Who is sponsoring clinical trial NCT00138840?
This trial is sponsored by Synta Pharmaceuticals, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.